<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02152423</url>
  </required_header>
  <id_info>
    <org_study_id>ENOXAMED</org_study_id>
    <nct_id>NCT02152423</nct_id>
  </id_info>
  <brief_title>Enoxamed Study in the Treatment of Acute Coronary Syndromes</brief_title>
  <acronym>ENOXAMED</acronym>
  <official_title>Comparison of the Anti Xa Activity in the Enoxaparin for Acute Coronary Syndromes Admitted to the Emergency. Randomized Clinical Trial ENOXAMED Versus LOVENOX</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital Fattouma Bourguiba</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Because of their anti-Xa and ease of administration activity, the Low molecular weight
      heparin represent an attractive alternative to the unfractionated heparin. Several clinical
      trials have demonstrated that Low molecular weight heparin was more effective than
      Unfractionated heparin without increasing bleeding complications. Enoxaparin has been the
      most studied. Its use is recommended.

      Demonstrate that Enoxamed® is comparable to that of Lovenox® in the anti-Xa activity action.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center randomized controlled trial, single-blind, including patient with an acute
      coronary syndrome confirmed, to measure the anti-Xa activity between H0 and H4.the study was
      done on two groups ; ENOXAMED® group : In this case the patient receives an injection of
      enoxaparin ( ENOXAMED® ; Unimed Laboratories) intravenously. Curative dose (100 IU/10 kg).

      Control group ( LOVENOX ® ) In this case the patient receives LOVENOX intravenous injection
      curative dose of 100 kg IU/10 .
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>anti Xa activity (UI/ml)</measure>
    <time_frame>at baseline and after 4 hours</time_frame>
    <description>Compare the Anticoagulant Activity (measured in a UI per ml in a reference laboratory) of Two Formulations of Enoxaparin [ENOXAMED ® Versus LOVENOX ®], Conducted on Two Parallel Groups of Patients Admitted to Emergency for Acute Coronary Syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during hospital stay with an average of 5 days</time_frame>
    <description>Evaluate the Clinical and Biological Tolerance of the Study Treatments.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>LOVENOX</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>patients are given a curative dose of Enoxaparin (LOVENOX)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ENOXAMED</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients are given a curative dose of Enoxaparin (ENOXAMED)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LOVENOX</intervention_name>
    <arm_group_label>LOVENOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ENOXAMED</intervention_name>
    <arm_group_label>ENOXAMED</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age over 18 year old

          -  With an acute coronary syndrome confirmed

        Exclusion Criteria:

          -  Age less than 18 years

          -  Persistent ST- segment elevation

          -  Contre indication of enoxaparin and heparin in general.

          -  Patient participating in another study,

          -  Pregnant or nursing women

          -  patients taking an anticoagulant in the last three months,

          -  Patients with coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nouira Samir, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University hospital of Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emergency Department of University Hospital of Monastir</name>
      <address>
        <city>Monastir</city>
        <zip>5050</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <link>
    <url>http://www.urgencemonastir.com</url>
    <description>official website</description>
  </link>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2014</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Nouira</investigator_full_name>
    <investigator_title>Head of departement</investigator_title>
  </responsible_party>
  <keyword>enoxaparin</keyword>
  <keyword>Enoxamed</keyword>
  <keyword>lovenox</keyword>
  <keyword>anti Xa</keyword>
  <keyword>acute coronary syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

